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Summary Background: IV/PO moxifloxacin was evaluated in the treatment of
hospitalized patients with severe community-acquired pneumonia (CAP).
Methods: Data were pooled from two prospective, randomized studies. In the
multinational study, patients received 7–14 days IV/PO moxifloxacin 400mg QD or IV/
PO amoxicillin clavulanate 1200/625mg TID7IV/PO clarithromycin 500mg BID. In the
North American study, patients received 7–14 days IV/PO moxifloxacin 400mg QD, IV/
PO alatrofloxacin/trovafloxacin 200mg QD, or IV/PO levofloxacin 500mg QD. The
primary endpoint was clinical success at the test-to-cure visit. Severe CAP was
defined according to the 1993 ATS criteria.
Results: In the clinically valid population, clinical success rates were 88% (167/190)
for moxifloxacin- and 83% (155/186) for comparator-treated patients (95%
CI¼1.9%, 12.2%). Corresponding clinical success rates for the microbiologically
valid population were 87% (59/68) and 84% (54/64), respectively (95% CI¼8.6%,
15.0%). A switch from IV to PO therapy was made by day 5 of therapy for 73% of
moxifloxacin- vs. 60% of comparator-treated patients (Po0:01). Clinical success rates
were similar in a retrospective analysis using the revised 2001 ATS definition of severe
CAP. Mortality rates were 6% (15/241) and 10% (24/238) in the moxifloxacin and
comparator treatment groups, respectively. The incidence of drug-related adverse
events was similar in both treatment groups.
Conclusion: Sequential IV/PO moxifloxacin 400mg QD is as safe and effective as
other fluoroquinolones and a b-lactam/macrolide combination for treating hospita-
lized patients with severe CAP.
r 2003 Elsevier Ltd. All rights reserved.
KEYWORDS
Moxifloxacin;
Severe pneumonia;
Amoxicillin clavulanate;
Clarithromycin;
Levofloxacin;
Trovafloxacin
Introduction
Community-acquired pneumonia (CAP) remains a
prevalent and potentially life-threatening infec-
tion, with the US reporting almost 4 million new
cases and the UK diagnosing at least 250,000 adults
each year.1,2 Approximately 25–35% of new cases
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require hospitalization,1,2 and for critically ill
patients with CAP, mortality rates range from 5%
to as high as 30–50%1,3–5. Indeed, pneumonia is the
leading cause of infection-related mortality and is
responsible for an estimated 45,000 deaths per
year in the US.1
In general, CAP is considered severe when
hospitalization is required, and this often suggests
a poorer prognosis. Severe CAP in patients of any
age is usually characterized by one or more of the
following criteria: acute respiratory failure, hemo-
dynamic compromise, severe sepsis and septic
shock, multilobar radiographic infiltrates, plus
some additional laboratory parameters (e.g., blood
urea nitrogen47mM, lactate dehydrogen-
ase4260 U/l and low serum albumin at admis-
sion).6–8 Although there is no uniform objective
definition for severe CAP, patients with any of these
characteristics require hospitalization and prompt
antimicrobial treatment.1,7,9
Determining the etiology of CAP remains challen-
ging, with no pathogenic organism(s) being identi-
fied in up to 50% of patients. Despite the limitations
of current diagnostic tests, a concerted effort
should be made to identify the causative organism
in patients with severe CAP as this may confirm the
appropriateness of the empiric antimicrobial ther-
apy.1,7 Streptococcus pneumoniae, Haemophilus
influenzae, Staphylococcus aureus, aerobic Gram-
negative bacilli, Legionella spp., Mycoplasma
pneumoniae, and Chlamydia pneumoniae are the
most frequently isolated pathogens from patients
of any age who require hospitalization for CAP.1,7,10
The empiric antimicrobial regimen must be highly
effective against S. pneumoniae as this organism
has been identified as the etiologic pathogen in
nearly two-thirds of patients who have died of
pneumonia,11 and is the most commonly isolated
pathogen from the elderly and patients with
underlying medical conditions.1,7
Treatment of severe CAP is challenging and is
influenced by an extensive list of possible patho-
gens, new antimicrobial options, and emergence of
resistance to some antimicrobials especially against
S. pneumoniae.12–16 For hospitalized patients who
do not require admission to the intensive care unit
(ICU), the most recent guidelines published by the
Infectious Diseases Society of America (IDSA)
recommend monotherapy with a newer fluoroqui-
nolone or the combination of an extended-spec-
trum cephalosporin plus a macrolide.1 For the most
severe CAP episodes (i.e., those requiring ICU
admission), the IDSA has recommended the combi-
nation of a b-lactam (e.g., ceftriaxone, ampicillin
sulbactam) with either a macrolide or fluoroquino-
lone.1 Similar recommendations are found in the
most recent American Thoracic Society (ATS) 7 and
British Thoracic Society (BTS) guidelines.17 Follow-
ing initial improvement, some patients with severe
CAP may be candidates for sequential IV to oral
therapy.1,7,18–22
Moxifloxacin (Avelox; Bayer AG: Wuppertal,
Germany), a new 8-methoxy quinolone, has ex-
cellent and potent in vitro activity against both
typical Gram-negative and Gram-positive aerobes
and atypical pathogens commonly associated with
severe CAP.23,24 Further, moxifloxacin remains
active against penicillin-resistant S. pneumo-
niae23,24 Moxifloxacin’s pharmacokinetic/pharma-
codynamic profile permits once daily dosing and
bioequivalence of oral and IV formulations allows
for convenient sequential IV to PO therapy without
dosage adjustment.25 The aim of this pooled
analysis was to evaluate the efficacy and safety of
sequential (IV/PO) moxifloxacin compared with
standard IV/PO antimicrobials (i.e., other fluoro-
quinolones or a b-lactam/macrolide combination)
in the treatment of patients hospitalized with
severe CAP, including those considered to be
critically ill.
Patient population and methods
Patient selection
In this retrospective study of patients with severe
CAP, data were pooled from two prospective,
randomized clinical trials with moxifloxacin: one
multinational study was conducted in Europe, Israel
and South Africa; the other study was conducted in
North America. The patient eligibility criteria for
both the multinational and North American studies
were similar and included: ageX18 years with signs
and symptoms consistent with bacterial pneumonia
(mild to moderately severe CAP and severe CAP)
requiring IV therapy. CAP was documented by the
presence of fever and/or elevated WBC count
(410,000/mm3), WBC count p4500/mm3, or
X15% immature neutrophils plus a new or progres-
sive infiltrate on chest X-ray confirmed by a
radiologist. In addition, each patient had to have
at least one sign or symptom of pneumonia (i.e.,
productive cough, purulent sputum, dyspnea or
tachypnea (420 breaths/min), rigors/chills,
pleuritic chest pain, or signs of pulmonary con-
solidation). For the purposes of this retrospective
analyses, only patients classified as having severe
CAP (see below) were included.
Both trials excluded patients who resided in a
nursing home and those hospitalized for 448 h
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before the onset of pneumonia symptoms. Patients
were also excluded if they had a history of any of
the following: bronchial obstruction or post-ob-
structive pneumonia; suspected aspiration pneu-
monia or pulmonary tuberculosis; prior therapy
with a systemic antibiotic for 424 h prior to
enrollment (unless a failure with identification of
a pathogen); moderate to severe liver (Child-Pugh
B/C) or renal (ClCr o50ml/min) impairment;
prolonged QTc interval; using Class IA or III antiar-
rhythmics; uncorrected hypokalemia; absolute
neutrophil count o1000 cell/mm3 or significant
immunosuppression; and rapidly fatal underlying
disease.
Each patient provided written informed consent
following approval of the protocol by each institu-
tion’s internal review board and in accordance with
the Declaration of Helsinki.
Definition of severe CAP
In both the multinational and North American
studies, severe pneumonia was defined according
to the 1993 ATS criteria and included the presence
of at least one of the following conditions:
respiratory rate 430 breaths/min pretherapy,
PaO2/FIO2 ratio o250mmHg or PO2p8 kPa
(60mmHg); requirement for mechanical ventila-
tion; chest radiograph indicating bilateral or multi-
lobe involvement; increase in the size of opacity by
X50% within 48 h of admission; shock (systolic
blood pressure o90mmHg or diastolic pressure
o60mmHg); requirement for vasopressor therapy
for 44 h; and urine output o20ml/h or a total
urine output o80ml/h unless another explanation
was provided.26
Following completion of the multinational and
North American trials, new ATS guidelines were
published in 2001.7 The latest guidelines define
severe CAP as the presence of either one of two
major criteria (need for mechanical ventilation or
septic shock) or the presence of two of three minor
criteria (systolic blood pressure p90mmHg, multi-
lobar disease, and PaO2/FIO2 ratio o 250mmHg).7
Study design and antimicrobial therapy
Each study in this pooled analysis was a prospec-
tive, multi-center, Phase III clinical trial. The North
American study was double-blinded, while the
multinational investigation had an open-label de-
sign. Patients categorized with CAP were rando-
mized to receive either moxifloxacin (Avelox, Bayer
AG, Wuppertal, Germany), or a comparator anti-
biotic using a block random code that was
computer-generated.
In the multinational trial, patients were rando-
mized to either moxifloxacin or amoxicillin clavu-
lanate (Augmentin, SmithKline Beecham,
Philadelphia, PA). The following regimens were
administered: IV/PO moxifloxacin 400mg QD or IV/
PO amoxicillin clavulanate 1200/625mg TID7IV/
PO clarithromycin 500mg BID (Biaxin, Abbott
Laboratories, Chicago, IL).
In the North American trial, patients were
randomized to either IV/PO moxifloxacin QD
(Avelox, Bayer Corporation Pharmaceutical Divi-
sion, West Haven, CT) or IV/PO alatrofloxacin/
trovafloxacin 200mg QD (Trovan I.V./Trovan ta-
blets, Pfizer, Roerig, New York, NY). Following
concerns about trovafloxacin-related hepatotoxi-
city in late 1999, subsequently enrolled patients
were randomized to receive either moxifloxacin, or
IV/PO Levofloxacin 500mg QD (Levaquin, Ortho
Pharmaceutical Corporation, Raritan, NJ). A ‘‘dou-
ble-dummy’’ approach was used to maintain the
blinding.
In both trials, patients were to receive IV
antibiotic (each as 60min infusion) for at least 3
days. Each patient was to receive a total of 7–14
days of IV/PO therapy. The switch to the assigned
oral antibiotic was based on criteria previously
reported and included:27
* clinical response (resolution of fever, improved
cough and respiratory distress, improvement in
leukocytosis);
* chest radiographs (if deemed clinically neces-
sary) to determine if the condition was improv-
ing, unchanged or worsening;
* ability to tolerate oral therapy;
* no evidence of markedly decreased gastrointest-
inal motility or malabsorption; and
* the investigator’s judgement.
Efficacy and safety measurements
The effectiveness of the study drug was determined
by assessing the patients’ clinical response, as well
as the presumed or documented bacteriologic
response of the infecting organism. Microorganisms
were primarily isolated from sputum or blood.
The clinically valid population included patients
who satisfied the following criteria: (1) had no
protocol violations influencing efficacy; (2) had
radiologic evidence of new or progressive infiltrate
consistent with pneumonia; (3) received at least
48 h of antimicrobial therapy if a treatment failure
or at least 5 full days of therapy if a treatment
success; and (4) took no other antimicrobial agent
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with the study drug for the entire study period
unless they were a treatment failure. Clinical
response at the test-of-cure visit (5–7 days for
multinational trial vs. 7–30 days post-therapy for
the North American trial) was defined as Cure
(disappearance of acute signs and symptoms
related to the infection or sufficient improvement
such that additional or alternative antimicrobial
therapy was not required), Failure (insufficient
lessening of the signs and symptoms of infection
such that additional or alternative antimicrobial
therapy was required), or Indeterminate (a clinical
assessment was not possible for any reason).
Bacteriological responses were graded as eradi-
cation, presumed eradication (if no material was
available due to a clinical success), persistence,
presumed persistence (no material was available in
a patient considered a clinical failure), or indeter-
minate (if bacteriological response to the study
drug was not evaluable for any reason).
All patients receiving at least one dose of study
drug were evaluated for drug safety (intent-to-
treat population). Safety of study drug therapy was
monitored by clinical observations and by conven-
tional laboratory tests. Adverse events were rated
by the investigator as to their severity (mild,
moderate, severe), and by the relationship to the
study drug (probable, possible, remote, or none).
Statistical analyses
Demographic and baseline characteristics were
pooled for the two studies and summarized for
each treatment group (i.e., moxifloxacin vs.
comparator). These summaries included means,
standard deviations, medians, and quartiles for
continuous data and frequency counts for catego-
rical variables.
Two-sided 95% confidence interval (CI) were
constructed around the mean clinical success rates
using Mantel–Haenszel weights, using the sample
size of the respective studies as the weights.
Similar analyses were performed for the population
considered to be microbiologically valid and for the
intent-to-treat population (i.e., all patients who
received at least one dose of study drug). Clinical
success rates were calculated using the protocol-
derived definition of severe CAP. An exploratory,
retrospective analysis of the clinical success rates
was also performed using the new 2001 ATS
definition for severe CAP.
Comparison of the incidence of adverse events in
each treatment group was done in a descriptive
manner. Safety analyses included tabulations of
type (COSTART), frequency, duration, and drug-
relatedness of treatment-emergent events.
Results
The pooled analysis included a total of 479 severe
CAP patients who were randomized to receive a
study antibiotic in the two trials. Two hundred and
forty-one patients received moxifloxacin, and 238
patients received a comparator antimicrobial. A
total of 376 patients (190 moxifloxacin, 186
comparator) satisfied the a priori definition of
being clinically valid. A respiratory pathogen was
isolated pretherapy in 68 moxifloxacin- and 64
comparator-treated patients (microbiologically va-
lid population).
The demographics and baseline medical charac-
teristics of the intent-to-treat and clinically valid
populations suggest that the two treatment groups
were similar (Table 1). In general, patients with
severe CAP were male (460%) and Caucasian
(475%). The mean age was 57 years. The reason
most cited for severe CAP was bilateral or multi-
lobar pneumonia (49%). More than a third of
patients categorized with severe CAP had a
respiratory rate 430 bpm and/or a PaO2/FIO2 ratio
o250mmHg. Slightly more patients randomized to
moxifloxacin were in shock (30%) compared with
those given the comparator antimicrobial (24%).
Few patients required mechanical ventilation
(p2%).
Pretherapy pathogens
A total of 186 of 479 (39%) patients defined as
intent-to-treat had 252 potential pathogens identi-
fied pretherapy from the respiratory tract or blood.
Specifically, 97 moxifloxacin-treated patients had
129 pathogens and 89 comparator-treated patients
had 123 pathogens identified at baseline. The
following pathogens were most commonly identi-
fied from the respiratory tract: S. pneumoniae (38
moxifloxacin, 38 comparator), H. influenzae (21
moxifloxacin, 15 comparator), M. pneumoniae (11
moxifloxacin, 10 comparator), C. pneumoniae
(three moxifloxacin, six comparator), Legionella
spp. (one moxifloxacin, three comparator), and S.
aureus (eight moxifloxacin, seven comparator). Of
34 patients with an atypical pathogen identified
pretherapy, 11 had mixed infection (four moxiflox-
acin, seven comparator).
A total of five (three moxifloxacin, two compara-
tor) S. pneumoniae isolates were penicillin-resis-
tant (PRSP; MICX2 mg/ml). In addition, nine (five
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moxifloxacin, four comparator) H. influenzae iso-
lates produced b-lactamase. No S. aureus isolates
were found to be methicillin-resistant.
A total of 38 ITT patients had confirmed
bacteremia including 20 moxifloxacin- and 18
comparator-treated patients. S. pneumoniae was
the most frequently isolated organism causing
bacteremia (14 moxifloxacin, 11 comparator).
Other organisms included staphylococcal and strep-
tococcal species (e.g., S. aureus, Staphylococcus
epidermidis, Streptococcus viridans), H. influen-
zae, Bacillus cereus and Eschericia coli. No blood
isolates were PRSP.
Clinical response
For the clinically valid population, the mean total
length of antibiotic therapy was 1273 days for both
treatment groups. A switch from IV to PO therapy
was made by day 5 of therapy for 73% (139/190) of
moxifloxacin vs. 60% (112/186) of comparator-
treated patients (Po0:01). This significant differ-
ence in time of switch from IV to PO therapy was
driven predominantly by the superior performance
of moxifloxacin compared to the b-lactam/macro-
lide comparators. Similar durations of therapy and
time of IV to PO switch were observed for the
intent-to-treat and microbiologically valid popula-
tions.
Table 2 displays the clinical response at the test-
of-cure visit for the clinically valid, intent-to-treat,
and microbiologically valid groups. Under the 1993
ATS definition of severe CAP, for the clinically valid
population, clinical cure at the test-of-cure visit
was 88% for moxifloxacin compared with 83% for
the comparator regimen (95% CI¼1.9%, 12.2%).
Clinical success rates for those comprising the ITT
and microbiologically valid populations were 71%
moxifloxacin vs. 68% comparator (95% CI¼4.4%,
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Table 2 Clinical resolution at test of cure in patients with severe CAP.
Population Moxifloxacin n/N (%) Comparator n/N (%)
Intent-to-treat populationa 171/241 (71) 161/238 (68)
Clinically valid populationb 167/190 (88) 155/186 (83)
Microbiologically valid populationc 59/68 (87) 54/64 (84)
a95% CI¼4.4%, 12.0%.
b95% CI¼1.9%, 12.2%.
c95% CI¼8.6%, 15.0%.
Table 1 Demographic and baseline medical characteristics.
Intent-to-treat population Clinically valid population
Moxifloxacin
(N ¼ 241)
Comparator
(N ¼ 238)
Moxifloxacin
(N ¼ 190)
Comparator
(N ¼ 186)
Sex, no. (%) male 145 (60) 147 (62) 116 (61) 114 (60)
Race, no. (%) Caucasian 187 (79) 183 (77) 147 (77) 141 (75)
Mean age (years) at enrollment
(range)
58 (18–89) 57 (18–93) 58 (18–89) 56 (19–93)
Definition of severe
No. (%) respiratory rate430 bpm 98 (41) 95 (40) 78 (41) 73 (39)
No. (%) PaO2/FIO2 ratio
o250mmHg
93 (39) 99 (42) 73 (38) 80 (43)
No. (%) requiring mechanical
ventilation
4 (2) 3 (1) 4 (2) 1 (o1)
No. (%) with bilateral or
multilobar involvement
107 (44) 135 (57) 83 (44) 102 (54)
No. (%) with increases in opacity
on chest X-ray by X50% within
48 h of admission
1 (o1%) 1 (o1%) 1 (o1%) 0
No. (%) with shock 72 (30) 57 (24) 58 (31) 43 (23)
Mean duration of infection, days 5 5 5 5
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12.0%) and 87% moxifloxacin vs. 84% comparator
(95% CI¼8.6%, 15.0%), respectively.
In the retrospective analysis using the 2001 ATS
definition,7 39% (95 moxifloxacin vs. 92 compara-
tor) of the pooled population of 479 patients had
severe CAP. For the clinically valid population, 89%
of moxifloxacin- vs. 81% of comparator-treated
patients were clinical successes at the test-of-cure
visit. Clinical response rates for the intent-to-treat
group were 74% and 60%, respectively.
All five patients (three moxifloxacin, two com-
parator) with a pretherapy PRSP isolated from a
respiratory source were clinical cures at the test-
of-cure visit. Of the nine patients with a pretherapy
b-lactamase positive H. influenzae isolate, clinical
success was achieved in five moxifloxacin- and four
comparator-treated patients.
Both treatment regimens were effective in
treating patients with bacteremia: 95% (19/20)
moxifloxacin- vs. 94% comparator-treated patients
(17/18) were clinical successes. Both failures at the
test-of-cure visit occurred in patients with S.
pneumoniae infection (one moxifloxacin, one com-
parator).
Bacteriologic results
The bacteriological eradication rates for the most
commonly identified causative respiratory organ-
isms at the test-of-cure visit differed between the
two treatment groups (Table 3). For the three most
commonly isolated (non-atypical) respiratory
pathogensFS. pneumoniae, H. influenzae, and S.
aureusFrates of eradication were somewhat high-
er amongst those receiving moxifloxacin. All five
PRSP isolates (three moxifloxacin, two comparator)
were presumed eradications at the test-of-cure
visit. All b-lactamase producing H. influenzae were
eradicated (five moxifloxacin, four comparator). In
addition, all four patients (one moxifloxacin, three
comparator) infected with Legionella spp. achieved
bacteriologic eradication.
Among patients with bacteremia, 95% (19/20) of
moxifloxacin- and 94% (17/18) of comparator-
treated patients had the causative blood isolates
eradicated. S. pneumoniae, the primary blood
isolate, was successfully eradicated/presumed era-
dicated by both moxifloxacin (100%; 14/14) and
comparator antimicrobials (91%; 10/11).
Safety and tolerability
Among 479 patients with severe CAP who received
at least one dose of study drug, drug-related
adverse events were reported in 116 (48%) moxi-
floxacin-treated patients and 107 (45%) compara-
tor-treated patients (Table 4). The most common
drug-related adverse events experienced by both
treatment groups were diarrhea (6%) and abnormal
liver function tests (5%). Injection site reactions or
phlebitis also occurred at similar rates between the
two groups (5% moxifloxacin, 7% comparator).
A total of 8% of moxifloxacin- (n ¼ 19) and 5.5%
of comparator-treated patients (n ¼ 13) had study
drug discontinued prior to completion of the full
treatment course because of a drug-related ad-
verse event. For moxifloxacin-treated patients,
events leading to discontinuation of therapy in-
cluded abnormal liver function tests (n ¼ 4),
allergic reactions/rash (n ¼ 3), and atrial fibrilla-
tion (n ¼ 2). For comparator-treated patients, the
primary events that resulted in early drug disconti-
nuation included worsening pneumonia (n ¼ 2),
rash (n ¼ 2), and increased liver function tests
(n ¼ 2).
Fifteen (6%) moxifloxacin- and 24 (10%) com-
parator-treated patients with severe CAP died
during the study period. Nine patients (three
moxifloxacin, six comparator) died while still
receiving study drug. The majority of deaths in
both treatment groups were secondary to progres-
sion of the patient’s infection, development of
nosocomial infection, or to underlying illness.
Among the 39 patients who died, five (two
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Table 3 Eradication rates of most commonly isolated pretherapy causative organisms.
Organism Moxifloxacin n/N (%) Comparator n/N (%)
Respiratory site
S. pneumoniae 24/26 (92) 25/29 (86)
H. influenzae 14/16 (88) 7/10 (70)
M. pneumoniae 8/9 (89) 9/9 (100)
C. pneumoniae 3/3 (100) 4/4 (100)
S. aureus 2/3 (67) 2/4 (50)
Blood site
S. pneumoniae 14/14 (100) 10/11 (91)
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moxifloxacin, three comparator) had bacteremia,
32 (12 moxifloxacin, 20 comparator) were male, 25
(seven moxifloxacin, 18 comparator) had multi-
lobar infiltrates, and eight (three moxifloxacin, five
comparator) were in shock during study therapy.
Discussion
There is relatively little published data that
prospectively and rigorously examines initial em-
piric antimicrobial regimens for the treatment of
severe CAP, therefore the findings from this large
two-study pooled analysis are noteworthy. This
analysis demonstrates that sequential IV/PO moxi-
floxacin therapy in hospitalized patients with
severe CAP is at least as efficacious as sequential
IV/PO standard fluoroquinolone therapy or IV/PO b-
lactamþ /macrolide combination. These findings
were consistently upheld for the three populations
analyzed including intent-to-treat, clinically valid,
and microbiologically valid subsets. Indeed, in all of
patient populations analyzed, there was a general
trend toward superiority of moxifloxacin in both
clinical response and bacterial eradication. Indeed,
in the multinational study, from which a subset of
patients with severe pneumonia presented in this
study was derived, moxifloxacin was found to be
significantly superior to amoxicillin clavulanteþ /
clarithromycin in time of switch from IV to PO
therapy, as well as clinical and bacteriological
responses.28 Overall, our analysis provides support
for the recent IDSA and ATS treatment guidelines1,7
which recommend use of an empiric fluoroquino-
lone monotherapy with S. pneumoniae coverage as
one option for patients with severe CAP.
The two studies that comprise this pooled
analysis were designed in 1997 and used the
original 1993 ATS definition for categorizing pa-
tients with severe CAP.26 However, in an analysis of
the pooled data using the revised 2001 ATS criteria,
the clinical response rates remained similar be-
tween the two treatment groups.
S. pneumoniae, H. influenzae, Gram-negative
enteric bacteria (especially K. pneumoniae), and S.
aureus, as well as atypical organisms (e.g.,
Legionella spp.) are the pathogens most commonly
implicated in severe CAP.1,7 In accordance with
other studies,1 an etiology for our pooled popula-
tion with severe CAP was only established in about
one-third of clinically valid patients. S. pneumo-
niae was isolated from sputum in more than 40% of
severe CAP episodes and in more than 66% of
patients with bacteremia. Only five cases of PRSP
(penicillin MICX2 mg/ml) were identified in our
pooled population.
Overall, IV/PO moxifloxacin eradicated the ma-
jority of causative organisms, including 100%
(n ¼ 14) of S. pneumoniae isolates cultured from
blood. Moxifloxacin also provided excellent efficacy
against the commonly isolated intracellular patho-
gens, M. pneumoniae and C. pneumoniae, 89% and
100%, respectively. Although the number of pa-
tients with resistant organisms in this pooled
analysis was small, three moxifloxacin- and two
comparator-treated patients infected with PRSP
(isolates all from respiratory tract sites) were
clinically and bacteriologically cured. All b-lacta-
mase producing H. influenzae were eradicated and
associated with clinical cure following therapy with
moxifloxacin. Collectively, these data provide
bacteriologic evidence that moxifloxacin is effec-
tive against the most common pathogens impli-
cated in causing severe CAP.
Few deaths attributable to infection were ob-
served in our population of patients with severe
CAP. However, of the patients that did succumb,
many had conditions/characteristics that have
been previously defined as prognostic factors
indicative of an increased risk of mortality.11 Such
factors included bacteremia, shock, multilobar
infiltrates on chest X-ray, and male gender. As
such, the group who died was not that unexpected.
The two clinical studies pooled in this retro-
spective analysis were different in designFone
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Table 4 Incidence rates of drug-related adverse events
occurring in 42% of patients.
Adverse event Moxifloxacin
(N ¼ 241)
All comparator
(N ¼ 238)
n (%) n (%)
Any drug-
related event
116 (48) 107 (45)
Injection site
reaction/
phlebitis
12 (5) 17 (7)
Headache 5 (2) 3 (1)
Diarrhea 15 (6) 14 (6)
Nausea 8 (3) 8 (3)
Vomiting 5 (2) 7 (3)
Oral moniliasis 5 (2) 6 (3)
Insomnia 5 (2) 2 (o1)
Dizziness 5 (2) 4 (2)
Rash 3 (1) 5 (2)
Atrial
fibrillation
5 (2) 0 (0)
LFT
abnormalities
11 (5) 12 (5)
GGTP
increased
1 (o1) 5 (2)
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double blind, the other open label. However, the
eligibility criteria, the criteria used to classify
patients as having severe pneumonia and the
criteria used to evaluate the patients with respect
to clinical response were identical. As such, the
two trials enrolled very similar patient populations
and the patients were assessed in the same way.
Additionally, the objective clinical end-points (vital
signs, findings on physical exam, radiological find-
ings, etc.) minimized the risk of biased when
evaluating patients in the open-label study.
Approximately 10% of hospitalized patients with
CAP are categorized as having severe pneumonia. In
patients receiving such a diagnosis, mortality rates
are high and may exceed 30%, especially in the
elderly.1,3–5 Early recognition of severe CAP and the
prompt initiation of broad-spectrum empiric ther-
apy is, therefore, advocated to reduce the risk of
mortality.1,7 The most current IDSA and ATS CAP
guidelines recommend the use of fluoroquinolone
monotherapy as one option for hospitalized pa-
tients with severe CAP.1,7 Results from our pooled
analysis provide clinical and bacteriologic evidence
that a sequential IV/PO moxifloxacin regimen is at
least as effective as the comparator fluoroquino-
lones and a b-lactam/b-lactamase inhibitor plus
macrolide combination in the treatment of severe
CAP. Treatment with IV/PO moxifloxacin was
associated with a low mortality rate and few
untoward adverse reactions.
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